Fig. 1. The structure and biological characterization of ABC and its ProTides. (A) M1ABC, M2ABC and M3ABC were synthesized based on ProTide technology. (B) EC50 of ABC, M1ABC, M2ABC and M3ABC against HIV-1ADA were determined in MDMs. (C) Intracellular CBV-TP levels were measured after MDMs were treated with 10 μM free ABC, M1ABC, M2ABC or M3ABC for various times. (D) Cytotoxicity of ABC, M1ABC, M2ABC and M3ABC in MDMs. Results are shown as percentage of cell viability as compared to untreated MDMs. Data are presented as mean ± SD for n = 3 samples per group.
